Establishment Labs Holdings stock analysis
Establishment Labs Holdings (3E0) Stock Price & Analysis
3E0 Stock Chart & Stats
- Day’s Range
- EUR 61.38 - EUR 61.74
- 52-Week Range
- EUR 37.60 - EUR 83.28
- Previous Close
- EUR 62.32
- Volume
- N/A
- Average Volume (3M)
- 20
- Market Cap
- EUR 1.91B
- Enterprise Value
- EUR 2.15B
- Total Cash (Recent Filing)
- EUR 75.81M
- Total Debt (Recent Filing)
- EUR 269.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.67
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
U.S. And International Revenue Growth
Strong growth across both the U.S. and international businesses indicates expanding market reach rather than dependence on one geography. Continued account gains and international expansion can support durable revenue growth as Motiva adoption and procedure volumes increase over the next several quarters.
Improving Operating Leverage And Margins
The sharp improvement in adjusted EBITDA margin and operating expense efficiency shows that revenue growth is beginning to translate into operating leverage. If maintained, this can strengthen earnings quality, reduce the funding burden of expansion, and support the path toward sustainable profitability.
Motiva And Minimally Invasive Product Adoption
High reorder rates and rising surgeon utilization provide evidence of recurring product adoption rather than solely new-account demand. Rapid growth in minimally invasive products also broadens the portfolio and may deepen surgeon engagement, supporting longer-term share gains and revenue diversification.
Bears Say
Persistent GAAP Losses
The company has not yet converted strong gross margins and improving revenue into sustainable GAAP earnings. Continued losses constrain internally generated capital, increase reliance on external financing, and leave execution vulnerable if operating expenses do not scale efficiently with growth.
Highly Leveraged Capital Structure
Very high leverage reduces financial flexibility and leaves the company more dependent on improving profitability to stabilize its balance sheet. A thin equity cushion can limit investment choices, increase sensitivity to operating setbacks, and make future growth financing more consequential.
Reconstruction Approval And Hospital Adoption Timing
The reconstruction opportunity may take longer to contribute because regulatory approval is incomplete and hospital committee reviews can delay commercial adoption. This creates uncertainty around the timing of a potentially important growth channel and could push meaningful revenue contribution into the back half of 2027.
Establishment Labs Holdings News
3E0 FAQ
What was Establishment Labs Holdings’s price range in the past 12 months?
What is Establishment Labs Holdings’s market cap?
When is Establishment Labs Holdings’s upcoming earnings report date?
How were Establishment Labs Holdings’s earnings last quarter?
Is Establishment Labs Holdings overvalued?
Does Establishment Labs Holdings pay dividends?
What is Establishment Labs Holdings’s EPS estimate?
How many shares outstanding does Establishment Labs Holdings have?
What happened to Establishment Labs Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Establishment Labs Holdings?
What is the TipRanks Smart Score and how is it calculated?
Establishment Labs Holdings Stock Smart Score
Company Description
Establishment Labs Holdings
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Fillipo Peter Caldini
- Employees
- 1,004
- Website
- www.establishmentlabs.com
- Address
- 11401 century oaks terrace, Austin, TX, 78758, US
Establishment Labs Holdings (3E0) Earnings & Revenues
3E0 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial year-over-year revenue growth, major U.S. and minimally invasive momentum, improved adjusted profitability, first-ever positive free cash flow, raised 2026 guidance and a 25% growth outlook for 2027. The main challenges were seasonal sequential softness, Middle East weakness, lower-than-previously-guided gross margin, ongoing GAAP losses and uncertainty around the timing of reconstruction approval and hospital adoption.
View all DE:3E0 earnings summaries3E0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 10 | 0 | 2 |











